过去一年中添加的文章，按日期排序
[引用][C] Imatinib versus newer generation TKIs for upfront therapy in chronic phase chronic myeloid leukemia: What is the rationale for paying more to get the same …
JH Lipton - American Journal of Hematology - Wiley Online Library
56 天前 - … therapy for chronic myeloid leukemia (CML). 1 The authors raise some interesting
questions about utility and positioning of this drug in therapy. … Value is what you get.” Over the …
questions about utility and positioning of this drug in therapy. … Value is what you get.” Over the …
Tyrosine Kinase Inhibitor (TKI) Treatment Patterns in 5,261 Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients in “Real-Life” Settings: A Population-Based …
M Benmerad, J Chassetuillier, C Bouvier, PL Lecoq… - Blood, 2023 - Elsevier
317 天前 - … Most frequent TKIs used as 1 st and 2 nd lines were imatinib (73.1%), and
dasatinib (60.4%; Figure 1), respectively. From the 3 rd line, TKI patterns changed following the …
dasatinib (60.4%; Figure 1), respectively. From the 3 rd line, TKI patterns changed following the …